Dr. Carlo Incerti. Picture: Forbion

Forbion appoints Dr. Carlo Incerti as Operating Partner

Forbion, a European life science venture capital firm, today announces that Carlo Incerti, M.D., will be joining Forbion as Operating Partner, effective 1st January 2019.

A medical doctor by training, Dr. Carlo Incerti brings over three decades of experience in the biopharmaceutical industry. He will join Forbion from Sanofi Genzyme where he currently holds the position of Senior Vice President, Chief Medical Officer and Head of Global Medical Affairs.

Prior to its acquisition by Sanofi in 2011, Dr. Incerti held a number of positions of increasing scope and responsibility at Genzyme, working first in the Europe division in the Netherlands (1993-2010) before being appointed Senior Vice President of Global Market Access (2010-2011).

Prior to his time at Sanofi and Genzyme, Dr. Incerti was a founding shareholder, Board member and Chief Executive officer at Biofil S.r.l., a start-up active in the development, manufacturing and commercialisation of systems for leukocyte depletion of blood and derivatives, which was acquired by Fresenius Kabi of Germany in 1993.

Dr. Incerti is also Chairman of the Board at Molmed, S.p.a., a Member of the Governing Board of IMI, the Innovative Medicines Initiative, a Member of the Board of EuropaBio and a Founding Member and on the Consortium Assembly of IRDiRC, the International Rare Diseases Research Consortium.

In his spare time, Dr. Incerti is an avid tennis player, rock- and ice climber and competitor in historic car racing.